Antiviral activity and resistance of HCV NS5A replication complex inhibitors.
about
Treatment of chronic hepatitis C with direct-acting antivirals: The role of resistanceNew approaches in the treatment of hepatitis CResistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical ImplicationsNew era for management of chronic hepatitis C virus using direct antiviral agents: A reviewThe new era of hepatitis C virus therapyHepatitis C virus RNA replication depends on specific cis- and trans-acting activities of viral nonstructural proteinsChanges of shear-wave velocity by interferon-based therapy in chronic hepatitis C.Hepatitis C NS5A protein: two drug targets within the same protein with different mechanisms of resistance.Hepatitis C virus NS5A inhibitors and drug resistance mutations.Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection.An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver.Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies?All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.Physical and functional interaction between hepatitis C virus NS5A protein and ovarian tumor protein deubiquitinase 7B.Prevalence of hepatitis C virus (HCV) variants resistant to NS5A inhibitors in naïve patients infected with HCV genotype 1 in Tunisia.Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir.Cost Effectiveness of Daclatasvir/Asunaprevir Versus Peginterferon/Ribavirin and Protease Inhibitors for the Treatment of Hepatitis c Genotype 1b Naïve Patients in Chile.Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infectionA randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3.Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort.Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study.Benefit-risk assessment of new and emerging treatments for hepatitis C: focus on simeprevir and sofosbuvir.Efficacy of daclatasvir in hepatitis C virus.Ombitasvir: a potent pan-genotypic inhibitor of NS5A for the treatment of hepatitis C virus infection.New treatments for chronic hepatitis C: an overview for paediatricians.Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis C postorthotopic liver transplant: the randomized GALAXY study.Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis.Management of HCV in cirrhosis-a rapidly evolving landscape.Hepatitis C virus drug resistance-associated substitutions: State of the art summary.Dual daclatasvir and sofosbuvir for treatment of genotype 3 chronic hepatitis C virus infection.New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir.The role of HCV proteins on treatment outcomes.Prevention and management of treatment failure to new oral hepatitis C drugs.Frequency of Natural Resistance within NS5a Replication Complex Domain in Hepatitis C Genotypes 1a, 1b: Possible Implication of Subtype-Specific Resistance Selection in Multiple Direct Acting Antivirals Drugs Combination Treatment.Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time.Sofosbuvir/Velpatasvir: The First Pangenotypic Direct-Acting Antiviral Combination for Hepatitis C.NS5A inhibitors impair NS5A-phosphatidylinositol 4-kinase IIIα complex formation and cause a decrease of phosphatidylinositol 4-phosphate and cholesterol levels in hepatitis C virus-associated membranes.A pangenotypic, single tablet regimen of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C infection.Novel Treatment of Hepatitis C Virus Infection for Patients with Renal Impairment.Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study.
P2860
Q26740219-904F0354-B7C3-49E9-B360-659456CD2AE3Q26773271-3316DD98-4194-4524-B31E-6F96F97BCF3CQ26777408-720570F8-8D6F-48AA-84E8-3B3C647A82D7Q26800050-BF9071BE-2F5C-432A-AF57-2041D1A8EC0AQ28086947-7D4FAC55-4361-4F35-A01E-663C09C05108Q28546101-56B64748-68A4-4D31-9540-F34B78705A05Q30402571-D8CB5A4D-159B-49CE-8298-FC6439229C69Q34332546-4AB147B6-EADC-4F0F-824F-730FAA716A84Q34411617-92FA5875-2E4D-4C71-96AA-DEC9F5C0449CQ35044909-FFAC5834-52A4-4C6C-8312-B5EAC83BF230Q35100139-515EA4E1-A8AB-4202-B668-E29F8FEB68CAQ35491398-321C94BB-94F5-4989-A3A0-FF204E3347F5Q35538245-85450677-E893-4895-AC28-0A2473C7B642Q35674938-89405DA5-A06B-4D04-A17B-864058284DD7Q35735285-65FFE7A9-7776-472F-9BB0-BF48F8AEAFDFQ36158391-44280D72-9748-4F50-803A-12763AF49FFCQ36257494-501C0D47-E5DF-4499-AB12-05B02A490429Q37097611-CBBAE840-BDE4-4D0C-BA09-DADD3F7E126AQ37187994-4F6D1571-3054-4FA9-A722-FDC0D9C11697Q37398996-D2F6F37F-7EA7-47B6-8937-29472D4E2123Q37738808-2E1FCA49-DEE6-4277-8D3C-EF447435800AQ38204368-8D839851-3FAB-4AB7-894E-C49235D01873Q38233602-631A6F1B-EB8C-48DB-AC72-55920D231FCEQ38235178-21001EBD-5D2F-4AD6-B8C3-1A02A8A1E5F0Q38282842-91109CDD-311D-4F0A-9B1F-B2E16A55D009Q38384095-B4F9CE44-3D04-478D-A069-36EC34F75A12Q38398290-0BAE0F32-2750-4CCD-B608-4115B2049721Q38432047-51CFD825-9FEB-4431-B47C-149E3866F320Q38533619-FB782327-6779-40E3-9383-21519AD95169Q38631256-12F928DA-7B28-4379-A9D7-4F709BD58F08Q38664453-3A4B665B-CF0A-4701-BC15-60E69DF7C21CQ38668968-2F4892C4-77AF-4A00-A5C9-BB3764B95A9FQ38826624-8EE00359-D947-4114-A28E-5F2D5FCCD0DFQ38888859-E2ABACD4-9AB0-46D1-AA86-0E870B2EB4F2Q38893104-19A2EFAB-D139-4BCE-8798-960A630CDCB4Q38949900-21559AD0-EDEC-419C-AD70-C0D0C9150091Q38956355-E240F6DB-B7DF-4588-B014-0A125FD84224Q39090420-34AFE020-FC82-4D5E-9DA8-B308534A7537Q39092977-2091BB1C-333D-4AE6-A7C4-8F37EB2287ADQ40124188-A74E6399-319A-42FF-86B2-018BA52F3962
P2860
Antiviral activity and resistance of HCV NS5A replication complex inhibitors.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Antiviral activity and resistance of HCV NS5A replication complex inhibitors.
@en
type
label
Antiviral activity and resistance of HCV NS5A replication complex inhibitors.
@en
prefLabel
Antiviral activity and resistance of HCV NS5A replication complex inhibitors.
@en
P1476
Antiviral activity and resistance of HCV NS5A replication complex inhibitors.
@en
P2093
P304
P356
10.1016/J.COVIRO.2013.06.014
P577
2013-07-27T00:00:00Z